Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Islet cell antibodies are associated with β-cell failure also in obese adult onset diabetic patients

Gottsäter, A. LU ; Landin-Olsson, M. LU ; Lernmark, Å LU orcid ; Fernlund, P. LU and Sundkvist, G. LU (1994) In Acta Diabetologica 31(4). p.226-231
Abstract

To clarify the utility of islet cell antibodies (ICA) to correctly classify and predict insulin treatment in newly diagnosed diabetic subjects, ICA, body mass index (BMI), glycated hemoglobin (HbA1c), and fasting plasma C-peptide values were evaluated at and 3 years after diagnosis in 233 new, consecutively diagnosed, adult diabetic patients classified as obese or nonobese (National Diabetes Data Group, NDDG criteria). Among the 233 patients, 31 were nonobese ICA-positive (mean age at diagnosis 43±3 years), 55 nonobese ICA-negative (mean age at diagnosis 58±2 years), 7 obese ICA-positive (mean age at diagnosis 57±5 years), and 139 obese ICA-negative (mean age at diagnosis 58±1 years). Fasting C-peptide decreased (P<0.05)... (More)

To clarify the utility of islet cell antibodies (ICA) to correctly classify and predict insulin treatment in newly diagnosed diabetic subjects, ICA, body mass index (BMI), glycated hemoglobin (HbA1c), and fasting plasma C-peptide values were evaluated at and 3 years after diagnosis in 233 new, consecutively diagnosed, adult diabetic patients classified as obese or nonobese (National Diabetes Data Group, NDDG criteria). Among the 233 patients, 31 were nonobese ICA-positive (mean age at diagnosis 43±3 years), 55 nonobese ICA-negative (mean age at diagnosis 58±2 years), 7 obese ICA-positive (mean age at diagnosis 57±5 years), and 139 obese ICA-negative (mean age at diagnosis 58±1 years). Fasting C-peptide decreased (P<0.05) in nonobese ICA-positive patients who after 3 years showed lower BMI (22.6±0.6 versus 24.5±0.4;P<0.05), lower fasting C-peptide (0.14±0.06 nmol/l versus 0.71±0.07 nmol/l;P<0.001), and higher frequency of insulin treatment [28/31 (90%) versus 6/45 (13%);P<0.001] than nonobese ICA-negative patients. In obese ICA-positive patients, fasting C-peptide also decreased (Δ C-peptide 0.17±0.04 nmol/l;P<0.05) after diagnosis, and 3 years after diagnosis, obese ICA-positive patients showed lower BMI (25.7±1.2 versus 29.8±0.4;P<0.01) and fasting C-peptide (0.08±0.04 nmol/l versus 1.06±0.05 nmol/l;P<0.001) and higher HbA1c values (9.92%±0.68% versus 7.39%±0.21%;P<0.01) and a higher frequency of insulin treatment [7/7 (100%) versus 5/121 (4%);P<0.001] than obese ICA-negative patients. Therefore, ICA detected at diagnosis of diabetes in both obese and nonobese adult patients indicate β-cell dysfunction, high HbA1c levels, and progression to insulin dependency.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Autoimmunity, Fasting C-peptide, Islet cell antibody
in
Acta Diabetologica
volume
31
issue
4
pages
6 pages
publisher
Springer
external identifiers
  • scopus:0028588120
  • pmid:7888694
ISSN
0940-5429
DOI
10.1007/BF00571956
language
English
LU publication?
yes
id
5264826a-c5c4-4585-ba54-88225d0f75a1
date added to LUP
2019-09-11 09:04:03
date last changed
2024-03-13 08:11:03
@article{5264826a-c5c4-4585-ba54-88225d0f75a1,
  abstract     = {{<p>To clarify the utility of islet cell antibodies (ICA) to correctly classify and predict insulin treatment in newly diagnosed diabetic subjects, ICA, body mass index (BMI), glycated hemoglobin (HbA<sub>1c</sub>), and fasting plasma C-peptide values were evaluated at and 3 years after diagnosis in 233 new, consecutively diagnosed, adult diabetic patients classified as obese or nonobese (National Diabetes Data Group, NDDG criteria). Among the 233 patients, 31 were nonobese ICA-positive (mean age at diagnosis 43±3 years), 55 nonobese ICA-negative (mean age at diagnosis 58±2 years), 7 obese ICA-positive (mean age at diagnosis 57±5 years), and 139 obese ICA-negative (mean age at diagnosis 58±1 years). Fasting C-peptide decreased (P&lt;0.05) in nonobese ICA-positive patients who after 3 years showed lower BMI (22.6±0.6 versus 24.5±0.4;P&lt;0.05), lower fasting C-peptide (0.14±0.06 nmol/l versus 0.71±0.07 nmol/l;P&lt;0.001), and higher frequency of insulin treatment [28/31 (90%) versus 6/45 (13%);P&lt;0.001] than nonobese ICA-negative patients. In obese ICA-positive patients, fasting C-peptide also decreased (Δ C-peptide 0.17±0.04 nmol/l;P&lt;0.05) after diagnosis, and 3 years after diagnosis, obese ICA-positive patients showed lower BMI (25.7±1.2 versus 29.8±0.4;P&lt;0.01) and fasting C-peptide (0.08±0.04 nmol/l versus 1.06±0.05 nmol/l;P&lt;0.001) and higher HbA<sub>1c</sub> values (9.92%±0.68% versus 7.39%±0.21%;P&lt;0.01) and a higher frequency of insulin treatment [7/7 (100%) versus 5/121 (4%);P&lt;0.001] than obese ICA-negative patients. Therefore, ICA detected at diagnosis of diabetes in both obese and nonobese adult patients indicate β-cell dysfunction, high HbA<sub>1c</sub> levels, and progression to insulin dependency.</p>}},
  author       = {{Gottsäter, A. and Landin-Olsson, M. and Lernmark, Å and Fernlund, P. and Sundkvist, G.}},
  issn         = {{0940-5429}},
  keywords     = {{Autoimmunity; Fasting C-peptide; Islet cell antibody}},
  language     = {{eng}},
  month        = {{12}},
  number       = {{4}},
  pages        = {{226--231}},
  publisher    = {{Springer}},
  series       = {{Acta Diabetologica}},
  title        = {{Islet cell antibodies are associated with β-cell failure also in obese adult onset diabetic patients}},
  url          = {{http://dx.doi.org/10.1007/BF00571956}},
  doi          = {{10.1007/BF00571956}},
  volume       = {{31}},
  year         = {{1994}},
}